On January 7, 2016, a to initiate an adversary proceeding was filed in the bankruptcy case of KaloBios Pharmaceuticals, Inc. and its affiliates.
The filing was assigned docket number 14 and is described on the court’s official docket as follows:
Motion to Shorten // Motion of Gregory Rea, RTAT LLC, Edward H. Painter, Nancy Retzlaff, and Armistice Capital Master Fund, Ltd. for Expedited Hearing and Shortened Notice Regarding Motion to (I) Escrow Certain Funds; or Alternatively, (II) Expedite the Adversary Proceeding (related document(s)) Filed by Armistice Capital Master Fund, Ltd., Edward H. Painter, RTAT LLC, Gregory Rea, Nancy Retzlaff. (Attachments: # (1) Proposed Form of Order) (Ward, Matthew)
KaloBios Pharmaceuticals, Inc. filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on December 29, 2015. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 15-12628. The bankruptcy case is currently assigned to United States Bankruptcy Judge Laurie Selber Silverstein. The law firm of Morris, Nichols, Arsht & Tunnell LLP is acting as lead bankruptcy counsel to KaloBios Pharmaceuticals, Inc. in the bankruptcy case.